Abstract
AbstractBackgroundThe study objective was to estimate the incidence of COVID-19 infection, hospitalization, and deaths in Japan from September 2023 to August 2024 and potential impact of a Fall 2023 COVID-19 vaccine for adults ≥18 years on these outcomes.MethodsA previously developed Susceptible-Exposed-Infected-Recovered model for the United States (US) was adapted to Japan. The numbers of symptomatic infections, COVID-19– related hospitalizations, and deaths were calculated. Given differences in vaccination coverage, masking practices and social mixing patterns between the US and Japan, all inputs were updated to reflect the Japanese context. Vaccine effectiveness (VE) values are hypothetical, but predicted based on existing VE values of bivalent BA.4/BA.5 boosters against BA.4/BA.5 in Japan, from the VERSUS test-negative case-control study. Sensitivity analyses were performed.ResultsThe base case model predicts overall that there will be approximately 35.2 million symptomatic COVID-19 infections, 690,000 hospitalizations, and 62,000 deaths in Japan between September 2023 and August 2024. If an updated COVID-19 vaccine is offered to all adults aged 18 years and older in Fall 2023, the model predicts that 7.3 million infections, 275,000 hospitalizations and 26,000 deaths will be prevented. If vaccines are only given to those aged 65 years and older, only 2.9 million infections, 180,000 hospitalizations and 19,000 deaths will be prevented. Sensitivity analysis results suggest that hospitalizations and deaths prevented are most sensitive to initial vaccine effectiveness (VE) against infection and hospitalizations, and the waning rate associated with VE against infection. Symptomatic infections prevented was most sensitive to initial VE against infection and VE waning.ConclusionsResults suggest that a Fall 2023 COVID-19 vaccine would reduce total numbers of COVID-19 related infections, hospitalizations, and deaths.
Publisher
Cold Spring Harbor Laboratory
Reference28 articles.
1. Prime Minister’s Office of Japan. COVID-19 Vaccines Ongoing Topics. https://japan.kantei.go.jp/ongoingtopics/vaccine.html (accessed September 22 2023).
2. Ministry of Health Labour and Welfare of Japan. About the new coronavirus vaccine. https://www.mhlw.go.jp/content/10900000/001147163.pdf (accessed September 22 2023).
3. Ministry of Health Labour and Welfare. The 80th Meeting of the Adverse Reactions Subcommittee of the Immunization and Vaccine Subcommittee of the Health and Welfare Science Council, and the 5th Meeting of the Pharmaceutical Affairs and Food Sanitation Council in FY Reiwa 4 (jointly held). https://www.mhlw.go.jp/stf/shingi2/0000208910_00043.html (accessed July 15 2023).
4. Prime Minister’s Office of Japan. About the new coronavirus vaccine. https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html (accessed September 22 2023).
5. Ministry of Health Labour and Welfare of Japan. 55th Health Science Council Vaccination and Vaccine Subcommitteee. Regarding vaccination of the new coronavirsu vaccine from 2020 onward. September 8, 2023. https://www.mhlw.go.jp/content/10900000/001144459.pdf (accessed September 22 2023).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献